Researchers from the Antimicrobial Resistance (AMR) interdisciplinary research group at Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research enterprise in Singapore, in collaboration with Nanyang Technological University Singapore (NTU Singapore) and National University Hospital, have discovered a novel therapy by combining two antibiotics, rifaximin and clarithromycin, to treat Mycobacterium abscessus, a non-tuberculous mycobacterium (NTM) that causes chronic lung-related infections. Infections caused by NTM are a fast-growing health concern worldwide, particularly in the context of lung-related infections. Among NTMs, M. abscessus is one of the most prevalent, causing pulmonary infections…
